Replies to post #114221 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

the Q2 report out of the way today, could be clearing the way for follow on PR tomorrow.

Also I see this as significant confirmation of the expectations and interpretation some of us have voiced.

The respective trial designs are based on broad genomic and biomarker characterization, pharmacokinetic and pharmacodynamic modeling including data from patients in previous ANAVEX(TM) 2-73 trials, as well as preclinical translational science. To our knowledge, this is the first use of this approach in the design of clinical trials for Alzheimer's disease, Parkinson's disease and Rett syndrome, and marks a shift towards advancing implementation of precision medicine for these and other neurodegenerative and neurodevelopmental diseases